Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer

M Takeda, I Okamoto, K Nakagawa - Lung Cancer, 2015 - Elsevier
Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
被引用次数：189 相关文章

Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer

M Takeda, I Okamoto, K Nakagawa - Lung Cancer, 2015 - lungcancerjournal.info
Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …

[引用][C] Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer

M Takeda, I Okamoto, K Nakagawa - Lung Cancer, 2015 - cir.nii.ac.jp
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung
cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer

M Takeda, I Okamoto, K Nakagawa - Annals of Oncology, 2015 - annalsofoncology.org
Objectives: Three EGFR-TKIs-afatinib, erlotinib, and gefitinib-are available for the treatment
of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Given the long …

Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer

M Takeda, I Okamoto… - Lung cancer …, 2015 - pubmed.ncbi.nlm.nih.gov
Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)-
afatinib, erlotinib, and gefitinib-are available for the treatment of patients with EGFR mutation …

Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer

M Takeda, I Okamoto, K Nakagawa - Lung Cancer, 2015 - kyushu-u.elsevierpure.com
Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)-afatinib,
erlotinib, and gefitinib-are available for the treatment of patients with EGFR mutation-positive …

Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.

M Takeda, I Okamoto, K Nakagawa - Lung Cancer (Amsterdam …, 2015 - europepmc.org
Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)-
afatinib, erlotinib, and gefitinib-are available for the treatment of patients with EGFR mutation …

Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer

M Takeda, I Okamoto, K Nakagawa - Lung Cancer, 2015 - infona.pl
Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–afatinib,
erlotinib, and gefitinib–are available for the treatment of patients with EGFR mutation …